Jabłońska E, Kiersnowska-Rogowska B, Rogowski F, Parfieńczyk A, Puzewska W, Bukin M
Department of Immunology, Medical University of Bialystok, Poland.
Rocz Akad Med Bialymst. 2005;50:204-7.
Although many studies demonstrated expression of TNF family members in the course of B-CLL, there is a little known about relationships between soluble forms of these proteins. Furthermore, there is no study reported on effects of used therapy on this relation. The present study was designed to asses the relationships between the serum concentrations of sFas, sFasL and sTRAIL in patients with B-CLL regarding their correlation with clinical stage and used therapy.
We studied 40 patients with B-cell chronic lymphocytic leukemia (B-CLL) at diagnosis, before treatment and four weeks after therapy. To measure sFas, sFasL and sTRAIL levels in serum commercially available ELISA kits were used.
We found increased concentrations of sFas in sera of all patients with B-CLL before treatment in comparison to the control group. There were no significant differences in concentrations of sFasL and sTRAIL between patients and control group. Increased sFasL concentrations after FC and CC therapy as well as decreased concentrations after 2CdA therapy in comparison to values before treatment were found. The concentrations of sTRAIL after FC and CC therapy were higher than those in patients before treatment.
Results obtained suggest that relationship between sFas, sFasL and sTRAIL in sera of patients with B-CLL before treatment may facilitate the growth B leukemic cells. Changes in these relations after therapy with FC and CC can make a contribution to inhibit B cells growth on the apoptosis way in this patient group.
尽管许多研究表明肿瘤坏死因子（TNF）家族成员在B细胞慢性淋巴细胞白血病（B-CLL）病程中表达，但对于这些蛋白的可溶性形式之间的关系却知之甚少。此外，尚无关于所用治疗方法对这种关系影响的研究报道。本研究旨在评估B-CLL患者血清中可溶性Fas（sFas）、可溶性Fas配体（sFasL）和可溶性肿瘤坏死因子相关凋亡诱导配体（sTRAIL）的浓度之间的关系，及其与临床分期和所用治疗方法的相关性。
我们研究了40例B细胞慢性淋巴细胞白血病患者，分别在诊断时、治疗前及治疗后四周进行观察。采用市售酶联免疫吸附测定（ELISA）试剂盒检测血清中sFas、sFasL和sTRAIL水平。
我们发现，与对照组相比，所有B-CLL患者治疗前血清中sFas浓度均升高。患者组与对照组之间sFasL和sTRAIL浓度无显著差异。与治疗前相比，发现氟达拉滨（FC）和环磷酰胺（CC）治疗后sFasL浓度升高，而2-氯脱氧腺苷（2CdA）治疗后浓度降低。FC和CC治疗后sTRAIL浓度高于治疗前患者。
所得结果表明，B-CLL患者治疗前血清中sFas、sFasL和sTRAIL之间的关系可能促进白血病B细胞生长。FC和CC治疗后这些关系的变化可能有助于通过凋亡途径抑制该患者组B细胞生长。
